Stage 5 Chronic Kidney Disease
Conditions
Keywords
Incident, Hemodialysis
Brief summary
Patients with end-stage renal disease are most vulnerable in the early months following hemodialysis (HD) initiation. Data from the United States Renal Data System and Singapore Renal Registry showed high mortality rates in the first 3-12 months of dialysis. Comprehensive multidisciplinary intervention programs implemented in the initial 3-4 months of dialysis showed reduction in mortality and morbidity in incident dialysis patients in the United States. Based on these models, the Hemodialysis Initiation and Transition (HIT) Clinic involving a renal physician, clinical pharmacist and coordinator was set up. The main aim of the clinic is to provide multidisciplinary, intensive and consistent care to patients in the first 3 to 4 months after HD initiation to focus on and streamline the management of dialysis issues and complications. These interventions would help patients achieve goal therapeutic targets, as well as reduce hospitalization rates and mortality, thereby improving their clinical outcomes and self-reported quality of life, and could result in economic and cost savings for the patients and healthcare system. The purpose of this study is to determine if the multidisciplinary, intensive and collaborative management of our multiethnic Asian patients newly-initiated on HD improves laboratory, clinical, economic and patient-reported outcomes. Adult incident HD patients from NUH will be randomized to the HIT clinic or to conventional management. Information on demographics, medical/medication histories, laboratory data (dialysis adequacy, iron-deficiency anemia, mineral/bone disorder, malnutrition and diabetes), hospitalizations, deaths and medical costs will be obtained and compared between the 2 groups. Patient-reported outcomes will be measured using the Kidney Disease Quality of Life-Short Form, EuroQol 5 Dimensions, Family Functioning Measure, Oslo-3 Social Support Scale and Health Services Utilization questionnaires. Data collection will take place at baseline, 3 to 4 months and 12 months after the first visit, with a total study duration and follow-up period of 1 year.
Interventions
OTHERMultidisciplinary, intensive and collaborative care
No specific study drugs, devices or procedures are involved. Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications.
Sponsors
National University of Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* all patients who are newly-initiated on HD and who meet the following criteria will be included in the study: * male or female 21 years of age or older with stage 5 CKD (eGFR \< 15 ml/min/1.73m2) * newly-initiated on HD within the past 4-8 weeks of being seen in the NUH outpatient renal clinic
Exclusion criteria
* transient HD patients * patients with poor cognitive function or are not able to complete the PRO questionnaires.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical (mortality and morbidity) | One year | Mortality and morbidity (hospitalization from uncontrolled hypertension, anemia and fluid overload) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory outcomes | One year | Lab results |
| Economic outcomes | One year | Direct and indirect medical costs |
| Patient-reported outcomes | One-year | KDQOL and other social support questionnaires |
Countries
Singapore
Contacts
Primary ContactPriscilla P How, Pharm.D., BCPS
Outcome results
None listed